Previous 10 | Next 10 |
CytoDyn ( OTCQB:CYDY +10.1% ) has completed the rolling submission of its U.S. marketing application seeking approval to use leronlimab, combined with highly active antiretroviral therapy (HAART), in treatment-experienced HIV patients, a Fast Track-tagged indication. More news on: Cyto...
VANCOUVER, Washington, April 27, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, today an...
During the FDA’s review period, the Company will dedicate all resources to ensure availability of leronlimab for COVID-19 patients; Cancer programs continue with positive results VANCOUVER, Washington, April 27, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“C...
VANCOUVER, Washington, April 24, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announce...
April 23, 2020 Palm Beach, FL – April 23, 2020 – America’s biopharmaceutical companies have recently reiterated that they are committed to developing solutions to help diagnose and treat those with COVID-19, a disease caused by a novel strain of coronavirus. I...
CytoDyn's ( CYDY ) most recent (4/17/20) Wall Street Live, " Next Superstock " promo, was worth the time invested for those who are trying to make sense of a CytoDyn investment. It was a new format with CytoDyn's hard-working CEO Nader Pourhassan [NP] moderating a series of questions for CytoD...
Introduction CytoDyn ( CYDY ) shares have been on a tear over the last few months, moving from just under $0.30 in December to an intraday high of ~$3.50 merely months later. From signing a commercialization deal with Vyera to launching a promising basket trial in over 20 different metasta...
CytoDyn Treats First Patient In Leronlimab Trial CytoDyn Inc. ( CYDY ) reported that it has treated the first patient in its Phase 2 basket trial for 22 solid cancer tumors. The trial deals with a wide range of cancers and tumors such as throat, stomach, lungs, bladder, and uterine among o...
VANCOUVER, Washington, April 20, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announce...
VANCOUVER, Washington, April 16, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announce...
News, Short Squeeze, Breakout and More Instantly...
Terms of the settlement include $12,000,000 cash payment to CytoDyn and elimination of $14,000,000 accounts payable liability from the Company’s balance sheet VANCOUVER, Washington, July 09, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a bio...
VANCOUVER, Washington, June 27, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that its preclinical MASH study with SMC ...
VANCOUVER, Washington, May 28, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Dr. Jacob P. Lalezari, Chief Executiv...